復(fù)方丹參注射液聯(lián)合丁苯酞注射液治療急性缺血性腦卒中的臨床研究
發(fā)布時(shí)間:2018-07-14 16:17
【摘要】:目的觀察復(fù)方丹參注射液聯(lián)合丁苯酞注射液治療急性缺血性腦卒中的臨床療效及安全性。方法將58例急性缺血性腦卒中患者作隨機(jī)分為試驗(yàn)組29例和對(duì)照組29例。對(duì)照組在常規(guī)治療的基礎(chǔ)上靜脈滴注丁苯酞注射液,每次25 mg,每日1次,持續(xù)治療14 d。而試驗(yàn)組在對(duì)照組的基礎(chǔ)上靜脈滴注復(fù)方丹參注射液,每次20 m L,每日1次,持續(xù)治療14 d,比較2組患者的臨床療效、治療前后的神經(jīng)功能缺損評(píng)分、血清炎癥因子水平[白細(xì)胞介素-6(IL-6)、IL-10、IL-β、腫瘤壞死因子-α(TNF-α)、超敏C反應(yīng)蛋白(hs-CRP)],以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對(duì)照組的總有效率分別為93.10%(27/29例)和72.41%(21/29例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組和對(duì)照組的神經(jīng)功能缺損評(píng)分分別為(11.03±3.05),(19.28±3.11)分;IL-6分別為(3.12±1.13),(5.21±1.43)ng·L~(-1);IL-10分別為(10.32±2.56),(8.52±2.15)ng·L~(-1);IL-β分別為(0.21±0.11),(10.42±0.29)ng·L~(-1);TNF-α分別為(8.32±1.35),(10.86±2.13)mg·L~(-1);hs-CRP分別為(2.01±0.65),(3.11±1.09)mg·L~(-1),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。試驗(yàn)組和對(duì)照組發(fā)生的藥物不良反應(yīng)主要有肺部感染和腦疝,試驗(yàn)組和對(duì)照組的藥物不良反應(yīng)發(fā)生率分別為17.24%和51.27%,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論復(fù)方丹參注射液聯(lián)合丁苯酞注射液能顯著改善患者的神經(jīng)功能缺損和血清炎癥因子水平,治療急性缺血性腦卒中的臨床療效顯著,且安全性較高。
[Abstract]:Objective to observe the efficacy and safety of compound salvia miltiorrhiza injection combined with butyphthalide injection in the treatment of acute ischemic stroke. Methods 58 patients with acute ischemic stroke were randomly divided into trial group (n = 29) and control group (n = 29). In the control group, butyphthalide injection was injected intravenously on the basis of routine treatment, 25 mg / time, once a day, for 14 days. On the basis of the control group, compound salvia miltiorrhiza injection was injected intravenously once a day for 14 days. The clinical efficacy and neurological deficit score before and after treatment were compared between the two groups. Serum levels of inflammatory cytokines [interleukin-6 (IL-6) IL-10 IL-10 IL- 尾, tumor necrosis factor- 偽 (TNF- 偽), hypersensitive C-reactive protein (hs-CRP)] and adverse drug reactions were observed. Results after treatment, the total effective rates of the experimental group and the control group were 93.10% (27 / 29 cases) and 72.41% (21 / 29 cases), respectively. The difference was statistically significant (P0.05). 娌葷枟鍚,
本文編號(hào):2122215
[Abstract]:Objective to observe the efficacy and safety of compound salvia miltiorrhiza injection combined with butyphthalide injection in the treatment of acute ischemic stroke. Methods 58 patients with acute ischemic stroke were randomly divided into trial group (n = 29) and control group (n = 29). In the control group, butyphthalide injection was injected intravenously on the basis of routine treatment, 25 mg / time, once a day, for 14 days. On the basis of the control group, compound salvia miltiorrhiza injection was injected intravenously once a day for 14 days. The clinical efficacy and neurological deficit score before and after treatment were compared between the two groups. Serum levels of inflammatory cytokines [interleukin-6 (IL-6) IL-10 IL-10 IL- 尾, tumor necrosis factor- 偽 (TNF- 偽), hypersensitive C-reactive protein (hs-CRP)] and adverse drug reactions were observed. Results after treatment, the total effective rates of the experimental group and the control group were 93.10% (27 / 29 cases) and 72.41% (21 / 29 cases), respectively. The difference was statistically significant (P0.05). 娌葷枟鍚,
本文編號(hào):2122215
本文鏈接:http://sikaile.net/yixuelunwen/shenjingyixue/2122215.html
最近更新
教材專著